Table 1.
Study dataset summary and key baseline patient characteristics
| Indication | Trial | n (%) | Age (years) mean (SD, range) | BCVA letter score at baseline mean (SD, range), Snellen equivalents |
|---|---|---|---|---|
| DME | RESTORE [5] | 344 (13.8) | 64 (9, 37–87) | 73 (11, 20/32) 96–40 (20/12–20/160) |
| Macular edema due to branch RVO | BRAVO [28] | 392 (15.8) | 66 (12, 26–91) | 82 (11, 20/25) 99–29 (20/10–20/250) |
| Macular edema due to central RVO | CRUISE [27] | 385 (15.5) | 68 (13, 20–91) | 81 (11, 20/25) 100–29 (20/10–20/250) |
| Neovascular AMD | ANCHOR [25] | 418 (16.8) | 77 (8, 53–96) | 68 (18, 20/40) 100–2 (20/10–20/1000) |
| Neovascular AMD | MARINA [26] | 716 (28.8) | 77 (7, 52–95) | 68 (15, 20/40) 99–19 (20/10–20/400) |
| CNV secondary to PM | RADIANCE [8] | 232 (9.3) | 56 (14, 18–87) | 73 (13, 20/32) 95–30 (20/12–20/250) |
| Overall population | 2487 (100) | 64 (9, 18–96) | 73 (15, 20/32) 100–2 (20/10–20/1000) |
AMD age-related macular degeneration, BCVA best-corrected visual acuity, BSE better-seeing eye, CNV choroidal neovascularization, DME diabetic macular edema, PM pathologic myopia, RVO retinal vein occlusion, SD standard deviation, VEGF vascular endothelial growth factor